JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online July 16, 2008, 10.2967/jnumed.108.052654
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.108.052654v1
49/8/1395    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hay, I. D.
Right arrow Articles by Sisson, J. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hay, I. D.
Right arrow Articles by Sisson, J. C.
Journal of Nuclear Medicine Vol. 49 No. 8 1395-1397
© 2008 by Society of Nuclear Medicine

doi: 10.2967/jnumed.108.052654

Special Contribution

Perspective: The Case Against Radioiodine Remnant Ablation in Patients with Well-Differentiated Thyroid Carcinoma

Ian D. Hay1, I. Ross McDougall2 and James C. Sisson3

1 Division of Endocrinology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota; 2 Division of Nuclear Medicine and Molecular Imaging, Stanford University Hospital and Clinics, Stanford, California; and 3 Division of Nuclear Medicine, Department of Radiology, University of Michigan Health System, Ann Arbor, Michigan

Correspondence: For correspondence or reprints contact: James C. Sisson, Division of Nuclear Medicine, Department of Radiology, Hospital B1 G505D, University of Michigan Health System, Ann Arbor, MI 48109-0028. E-mail: jsisson{at}umich.edu

We take issue with the stance that postoperative radioiodine remnant ablation should be applied ubiquitously as adjuvant therapy in patients with well-differentiated thyroid carcinoma. In this article, we state the reasons that we believe a compelling case can be made against ablation in most patients.

Key Words: endocrinology • oncology • radionuclide therapy • ablation • radioiodine • thyroid carcinoma

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  



This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
N. Aide, N. Heutte, J.-P. Rame, E. Rousseau, C. Loiseau, M. Henry-Amar, and S. Bardet
Clinical Relevance of Single-Photon Emission Computed Tomography/Computed Tomography of the Neck and Thorax in Postablation 131I Scintigraphy for Thyroid Cancer
J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 2075 - 2084.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
P. Bourgeois
A Proposition for the Use of Radioiodine in WDTC Management
J. Nucl. Med., February 1, 2009; 50(2): 328 - 329.
[Full Text] [PDF]


Home page
JNMHome page
I. D. Hay, I. R. McDougall, and J. C. Sisson
Reply: A Proposition for the Use of Radioiodine in WDTC Management
J. Nucl. Med., February 1, 2009; 50(2): 329 - 330.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2008 by the Society of Nuclear Medicine.